Patent ID: 8367638

Claim:
A method comprising the steps of: Obtaining a composition for parenteral administration comprising a selectively depolymerized galactomannan compound in an acceptable pharmaceutical carrier, wherein the selectively depolymerized galactomannan compound is a poly-β-1,4-mannan backbone, with galactose side substituents bound via α-1,6-glycoside linkages; and Administering to a subject having at least one of the following: chronic liver disease associated with the development of fibrosis, established liver fibrosis, or cirrhosis an effective dose of the composition for parenteral administration that results in at least one of the following: Inhibition or slowing down of progression of liver fibrosis or cirrhosis or reduction of established liver fibrosis or cirrhosis based on evidence comprising reduction of the level of biochemical markers of liver fibrosis, non invasive testing of liver fibrosis or cirrhosis or liver histologic grading of fibrosis or cirrhosis; wherein, when the composition for parenteral administration is utilized to treat LX2 immortalized human hepatic stellate cells in a MTT cell viability assay, the assay treatment results in substantially no decreased viability of activated hepatic stellate cells following administration of the composition.